局部晚期食管癌同步放化疗进展

doi:10.3760/cma.j.issn.1673422X.2014.08.012

摘要/Abstract

摘要： 食管癌的综合治疗已成为国内外广泛接受的治疗模式，主要的治疗方式有手术、放疗及化疗，其中放化疗占有相当重要的地位。多个随机对照研究及meta分析显示，术前新辅助放化疗及根治性同步放化疗对于局部晚期食管癌是首选的治疗方式。

Abstract: Comprehensive therapy is widely received for esophageal carcinoma in our country and worldwide. The treatment approaches consist of sugery, radiotherapy and chemotherapy, and chemoradiation therapy is very important. Many randomized controlled studies and metaanalysis reveal that preoperative neoadjuvant chemoradiotherapy and radical concurrent chemoradiation are the preferred modalities for local advanced esophageal carcinoma.

Key words: Esophageal neoplasms, Radiotherapy, Drug therapy

张光明,毛文奎,黄德波,张雪伟. 局部晚期食管癌同步放化疗进展[J]. 国际肿瘤学杂志, 2014, 41(8): 595-598.

Zhang Guangming, Mao Wenkui, Huang Debo, Zhang Xuewei. Concurrent chemoradiation for local advanced esophageal carcinoma[J]. Journal of International Oncology, 2014, 41(8): 595-598.

参考文献

［1］ Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781［J］. J Clin Oncol, 2008, 26(7): 1086-1092. ［2］ Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of longlasting pathological complete response: a phase 2 study［J］. Cancer, 2013, 119(5): 939945. ［3］ van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer［J］. N Engl J Med, 2012, 366(22): 20742084. ［4］ Kranzfelder M, Schuster T, Geinitz H, et al. Metaanalysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for oesophageal squamous cell cancer［J］. Br J Surg, 2011, 98(6): 768-783. ［5］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7): 681-692. ［6］ Hong JC, Murphy JD, Wang SJ, et al. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEERMedicare analysis［J］. Ann Surg Oncol, 2013, 20(12): 3999-4007. ［7］ Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of longlasting pathological complete response: a phase 2 study［J］. Cancer, 2013, 119(5): 939-945. ［8］ Spigel DR, Greco FA, Meluch AA, et al. Phase Ⅰ/Ⅱ trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction［J］. J Clin Oncol, 2010, 28(13): 2213-2219. ［9］ Wu S, Chen MY, Luo JC, et al. Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma［J］. Zhonghua Zhong Liu Za Zhi, 2012, 34(11): 873876. ［10］ Blom RL, Sosef MN, Nap M, et al. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma［J］. Dis Esophagus, 2014, 27(4): 380-387. ［11］ Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 9405) phase Ⅲ trial of combinedmodality therapy for esophageal cancer: highdose versus standarddose radiation therapy［J］. J Clin Oncol, 2002, 20(5): 11671174. ［12］ Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102［J］. J Clin Oncol, 2007, 25(10): 1160-1168. ［13］ Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma［J］. Dis Esophagus, 2010, 23(3): 253-259. ［14］ Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensitymodulated radiotherapy for upper esophageal carcinoma［J］. Radiat Oncol, 2013, 8: 75. ［15］ Conroy T, Yataghene Y, Etienne PL, et al. Phase Ⅱ randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer［J］. Br J Cancer, 2010, 103(9): 1349-1355. ［16］ Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial［J］. Lancet Oncol, 2014, 15(3): 305-314. ［17］ Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S1, and cisplatin for locally advanced esophageal cancer: longterm results of a phase Ⅱ trial［J］. Oncology, 2013, 84(6): 342349. ［18］ Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus［J］. J Clin Oncol, 2005, 23(10): 2310-2317. ［19］ Gwynne S, Hurt C, Evans M, et al. Definitive chemoradiation for oesophageal cancera standard of care in patients with nonmetastatic oesophageal cancer［J］. Clin Oncol (R Coll Radiol), 2011, 23(3): 182-188. ［20］ Piessen G, Messager M, Mirabel X, et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intentiontotreat casecontrol study［J］. Ann Surg, 2013, 258(5): 793-780. ［21］ Kogo M, Suzuki A, Sunaga T, et al. Scoring system for predicting recurrence after chemoradiotherapy including 5fluorouracil and platinum for patients with esophageal cancer［J］. Hepatogastroenterology, 2013, 60(128): 1979-1984. ［22］ Tan S, Kligerman S, Chen W, et al. Spatialtemporal ［18F］ FDGPET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy［J］. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1375-1382. ［23］ Eng CW, Fuqua JL 3rd, Grewal R, et al. Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PETCT useful?［J］. Clin Imaging, 2013, 37(3): 468-474. ［24］ Alexander BM, Wang XZ, Niemierko A, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): 164-171. ［25］ Chen PC, Chen YC, Lai LC, et al. Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1996-2003. ［26］ Pan JY, Ajani JA, Gu J, et al. Association of AuroraA (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation［J］. Cancer, 2012, 118(17): 4346-4353.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[8]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[9]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[10]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[11]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[12]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[15]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.